Pharma / Biotech

Exenatide implant therapy in diabetes.

Related Articles

Exenatide implant therapy in diabetes.

J Pak Med Assoc. 2018 Oct;68(10):1538-1540

Authors: Kalra S, Saboo B

Abstract
This review describes a recent advance in diabetes pharmacotherapeutics and drug delivery. ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it’s benefits can be utilized in clinical practice. It lists the advantages and limitations of the device, and shares tips for its rational use in type 2 diabetes care.

PMID: 30317359 [PubMed – in process]

Source link




Related posts

Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model.

Newsemia

MAKENA (hydroxyprogesterone caproate) injection [AMAG Pharmaceuticals, Inc.]

Newsemia

BURN RELIEF (Arsenic Trioxide, Atropa Belladonna, Lytta Vesicatoria, Causticum, Picric Acid, Urtica Urens, Hypericum Perforatum) Spray [Natrural Creations, Inc.]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy